NO914092L - Nye mercaptoacetylamid-derivater som er anvendbare som inhibitorer for enkefalinase og ace - Google Patents

Nye mercaptoacetylamid-derivater som er anvendbare som inhibitorer for enkefalinase og ace

Info

Publication number
NO914092L
NO914092L NO91914092A NO914092A NO914092L NO 914092 L NO914092 L NO 914092L NO 91914092 A NO91914092 A NO 91914092A NO 914092 A NO914092 A NO 914092A NO 914092 L NO914092 L NO 914092L
Authority
NO
Norway
Prior art keywords
ace
inhibitors
phalinase
enkey
new
Prior art date
Application number
NO91914092A
Other languages
English (en)
Other versions
NO180718B (no
NO914092D0 (no
NO180718C (no
Inventor
Gary Alan Flynn
Philippe Bey
Alan M Warshawsky
Douglas Wade Beight
Shujaath Mehdi
Eugene Lewis Giroux
Timothy Paul Burkholder
Original Assignee
Merrell Dow Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharma filed Critical Merrell Dow Pharma
Publication of NO914092D0 publication Critical patent/NO914092D0/no
Publication of NO914092L publication Critical patent/NO914092L/no
Publication of NO180718B publication Critical patent/NO180718B/no
Publication of NO180718C publication Critical patent/NO180718C/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO914092A 1990-10-18 1991-10-17 Analogifremgangsmåte for fremstilling av terapeutisk aktive mercaptoacetylamidderivater NO180718C (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60005290A 1990-10-18 1990-10-18
US73549691A 1991-07-25 1991-07-25

Publications (4)

Publication Number Publication Date
NO914092D0 NO914092D0 (no) 1991-10-17
NO914092L true NO914092L (no) 1992-04-21
NO180718B NO180718B (no) 1997-02-24
NO180718C NO180718C (no) 1997-06-04

Family

ID=27083513

Family Applications (1)

Application Number Title Priority Date Filing Date
NO914092A NO180718C (no) 1990-10-18 1991-10-17 Analogifremgangsmåte for fremstilling av terapeutisk aktive mercaptoacetylamidderivater

Country Status (18)

Country Link
EP (1) EP0481522B1 (no)
JP (1) JP3181335B2 (no)
KR (1) KR100372491B1 (no)
CN (2) CN1036590C (no)
AT (1) ATE161536T1 (no)
AU (1) AU642535B2 (no)
CA (1) CA2053340C (no)
DE (1) DE69128516T2 (no)
DK (1) DK0481522T3 (no)
ES (1) ES2114870T3 (no)
FI (2) FI95255C (no)
GR (1) GR3026222T3 (no)
HU (1) HU210008B (no)
IE (1) IE913648A1 (no)
IL (1) IL99769A (no)
NO (1) NO180718C (no)
NZ (1) NZ240230A (no)
PT (1) PT99267B (no)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208230A (en) * 1990-12-21 1993-05-04 Merrell Dow Pharmaceuticals Amino and nitro containing tricyclic compounds useful as inhibitors of ACE
ATE158303T1 (de) * 1990-12-21 1997-10-15 Merrell Pharma Inc Neue trizyklische amino- und nitro verbindungen mit ace-hemmenden eigenschaften
CA2078758C (en) * 1991-09-27 2003-12-09 Alan M. Warshawsky 2-substituted indane-2-mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace
US5457196A (en) * 1991-09-27 1995-10-10 Merrell Dow Pharmaceuticals Inc. 2-substituted indane-2-carboxyalkyl derivatives useful as inhibitors of enkephalinase and ACE
US5455242A (en) * 1991-09-27 1995-10-03 Merrell Dow Pharmaceuticals Inc. Carboxyalkyl tricyclic derivatives useful as inhibitors of enkephalinase and ace
AU657793B2 (en) * 1991-09-27 1995-03-23 Merrell Pharmaceuticals Inc. Novel 2-substituted indane-2-carboxyalkyl derivatives useful as inhibitors of enkephalinase and ACE
CA2078759C (en) * 1991-09-27 2003-09-16 Alan M. Warshawsky Novel carboxyalkyl derivatives useful as inhibitors of enkephalinase and ace
DE69317764T2 (de) * 1992-02-14 1998-07-30 Merrell Pharmaceuticals Inc., Cincinnati, Ohio Aminoacetylmercaptoacetylamid derivate mit enkephalinase- und ace-hemmwirkung
US5646276A (en) * 1992-05-13 1997-07-08 Bristol-Myers Squibb Co. Diazepine containing dual action inhibitors
US5552397A (en) * 1992-05-18 1996-09-03 E. R. Squibb & Sons, Inc. Substituted azepinone dual inhibitors of angiotensin converting enzyme and neutral exdopeptidase
ES2138622T3 (es) * 1992-05-15 2000-01-16 Merrell Pharma Inc Derivados de mercaptoacetilamido piridazo(1,2-a)(1,2)diazepina utilizados como inhibidores de encefalinasa y eca.
RU2124503C1 (ru) * 1992-05-18 1999-01-10 И.Р.Сквибб энд Санз, Инк. Гетероциклические азотсодержащие производные карбоновой кислоты, способ их получения и фармацевтическая композиция
US5238932A (en) * 1992-05-20 1993-08-24 Merrell Dow Pharmaceuticals Inc. Mercaptoacetylamide tricyclic derivatives useful as inhibitors of enkephalinase
US5298492A (en) * 1992-08-04 1994-03-29 Schering Corporation Diamino acid derivatives as antihypertensives
WO1994004531A1 (en) * 1992-08-24 1994-03-03 Merrell Dow Pharmaceuticals Inc. Novel 2-substituted indane-2-mercaptoacetylamide tricyclic derivatives useful as inhibitors of enkephalinase
US5208236A (en) * 1992-09-23 1993-05-04 Schering Corporation N-(acylaminomethyl)glutaryl amino acids and use
US5504080A (en) * 1992-10-28 1996-04-02 Bristol-Myers Squibb Co. Benzo-fused lactams
ES2155852T3 (es) * 1992-10-30 2001-06-01 Merrell Pharma Inc Derivados de lactama biciclica de mercaptoacetilamida utiles como inhibidores de encefalinasa y eca.
GB9310075D0 (en) * 1993-05-17 1993-06-30 Fujisawa Pharmaceutical Co New mercapto-amide derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same
AU680512B2 (en) * 1993-06-11 1997-07-31 Eisai Co. Ltd. Amino acid derivative
NZ267161A (en) * 1993-06-11 1996-12-20 Eisai Co Ltd Dipeptidic benzazepine derivative with ace inhibiting activity
US5508272A (en) * 1993-06-15 1996-04-16 Bristol-Myers Squibb Company Compounds containing a fused bicycle ring and processes therefor
JPH09500113A (ja) * 1993-06-30 1997-01-07 チバ−ガイギー アクチェンゲゼルシャフト エンケファリナーゼ及びａｃｅのインヒビターとして有用な抗高血圧性三環式アゼピン誘導体
ES2076096B1 (es) * 1993-07-14 1996-03-16 Squibb & Sons Inc Compuestos inhibidores de la enzima convertidora de angiotensinas y dela endopeptidasa neutra, y metodos para prepararlos.
US5362727A (en) * 1993-07-26 1994-11-08 Bristol-Myers Squibb Substituted azepino[2,1-a]isoquinoline compounds
US5525723A (en) * 1993-11-18 1996-06-11 Bristol-Myers Squibb Co. Compounds containing a fused multiple ring lactam
EP0750631B1 (en) * 1994-02-14 2000-04-05 Merrell Pharmaceuticals Inc. Novel mercaptoacetylamido 1,3,4,5-tetrahydro-benzo(c)azepin-3-one disulfide derivatives useful as inhibitors of enkephalinase and ace
CN1069317C (zh) * 1994-02-14 2001-08-08 默里尔药物公司 用作脑啡肽酶抑制剂的新的1,2－二氢化茚－2－巯基乙酰胺二硫化物衍生物
US5530013A (en) * 1994-02-14 1996-06-25 American Home Products Corporation Venlafaxine in the inducement of cognition enhancement
CN1046512C (zh) * 1994-02-14 1999-11-17 默里尔药物公司 巯基乙酰胺二硫化物衍生物，其制备方法及含有它们的药物组合物
WO1995021857A1 (en) * 1994-02-14 1995-08-17 Merrell Pharmaceuticals Inc. Novel 2-substituted indane-2-mercaptoacetylamide disulfide derivatives useful as inhibitors of enkephalinase and ace
US5484783A (en) * 1994-03-24 1996-01-16 Merrell Dow Pharmaceuticals Inc. Hypocholesterolemic, antiatherosclerotic and hypotriglyceridemic mercaptoacetylamide and benzazapine derivatives
CN1144482A (zh) * 1994-03-24 1997-03-05 默里尔药物公司 降低胆固醇、抗动脉粥样硬化和降低甘油三酯的巯基乙酰胺二硫化物衍生物
JPH09510476A (ja) * 1994-03-24 1997-10-21 メリル・フアーマシユウテイカルズ・インコーポレイテツド 低コレステロール血性、抗アテローム性動脈硬化性および低トリグリセライド血性のアミノアセチルメルカプト誘導体
US5616775A (en) * 1994-05-05 1997-04-01 Bristol-Myers Squibb Co. Process for preparing homocystein analogs useful as intermediates for compounds containing a fused bicyclic ring
US5641880A (en) * 1994-12-21 1997-06-24 Hoechst Marion Roussel, Inc. Processes for preparing intermediates of inhibitors of enkephalinase and angiotensin converting enzyme and intermediates thereof
HU227675B1 (en) * 1994-12-21 2011-11-28 Aventisub Ii Inc Novel processes for preparing intermediates of inhibitors of enkephalinase and angiotensin converting enzyme and intermediates thereof
US5587375A (en) * 1995-02-17 1996-12-24 Bristol-Myers Squibb Company Azepinone compounds useful in the inhibition of ACE and NEP
US5877313A (en) * 1995-05-17 1999-03-02 Bristol-Myers Squibb Benzo-fused azepinone and piperidinone compounds useful in the inhibition of ACE and NEP
US5635504A (en) * 1995-06-07 1997-06-03 Bristol-Myers Squibb Co. Diazepine containing dual action inhibitors
US5650408A (en) * 1995-06-07 1997-07-22 Karanewsky; Donald S. Thiazolo benzazepine containing dual action inhibitors
PT1087775E (pt) 1998-06-17 2005-11-30 Bristol Myers Squibb Co Prevencao de enfarte cerebral por administracao de uma combinacao de farmacos antiplaquetarios bloqueadores de receptores de adp e anti-hipertensivos
SE9903028D0 (sv) 1999-08-27 1999-08-27 Astra Ab New use
CA2382549C (en) 1999-08-30 2005-03-15 Aventis Pharma Deutschland Gmbh Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events
GB0119305D0 (en) 2001-04-12 2001-10-03 Aventis Pharma Gmbh Mercaptoacetylamide derivatives,a process for their preparation and their use
CZ299708B6 (cs) * 2001-04-12 2008-10-29 Sanofi - Aventis Deutschland GmbH Merkaptoacetylamidové deriváty, zpusob jejich prípravy a farmaceutické prostredky s jejich obsahem k ošetrování kardiovaskulárních onemocnení
AU2002348276A1 (en) 2001-11-16 2003-06-10 Bristol-Myers Squibb Company Dual inhibitors of adipocyte fatty acid binding protein and keratinocyte fatty acid binding protein
US7009047B2 (en) 2002-03-19 2006-03-07 Sanofi-Aventis Deutschland Gmbh Ethane-1,2-diaminium bis[(2R)-2-bromo-3-phenylpropanoate], processes for its preparation and its use
DE10212198A1 (de) * 2002-03-19 2003-10-02 Aventis Pharma Gmbh Ethan-1-diaminium-bis(2R)-2-brom-3-phenylpropanoat), Verfahren zu dessen Herstellung und dessen Verwendung
DE10229180A1 (de) 2002-06-28 2004-01-29 Aventis Pharma Deutschland Gmbh Verwendung von Vasopeptidase-Inhibitoren bei der Behandlung von metabolischen Erkrankungen, Nephropathie und mit AGE assoziierten Erkrankungen
JP4629657B2 (ja) 2003-04-11 2011-02-09 ハイ・ポイント・ファーマスーティカルズ、エルエルシー １１β−ヒドロキシステロイドデヒドロゲナーゼ１型化活性化合物
US7459474B2 (en) 2003-06-11 2008-12-02 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor and method
US7371759B2 (en) 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US7420059B2 (en) 2003-11-20 2008-09-02 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US7273881B2 (en) 2004-01-16 2007-09-25 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US9012494B2 (en) 2004-05-07 2015-04-21 Janssen Pharmaceutica N.V. Pyrrolidin-2-one and piperidin-2-one derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors
FR2872164B1 (fr) * 2004-06-29 2006-11-17 Aventis Pharma Sa Derives de quinoleines-4-substituees, leur procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent
DE602005017159D1 (de) 2004-08-30 2009-11-26 Janssen Pharmaceutica Nv Oxysteroid-dehydrogenase-inhibitoren
US7888381B2 (en) 2005-06-14 2011-02-15 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity, and use thereof
US7592461B2 (en) 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7795291B2 (en) 2006-07-07 2010-09-14 Bristol-Myers Squibb Company Substituted acid derivatives useful as anti-atherosclerotic, anti-dyslipidemic, anti-diabetic and anti-obesity agents and method
EP2099767A1 (en) 2006-11-01 2009-09-16 Brystol-Myers Squibb Company Modulators of glucocorticoid receptor, ap-1, and/or nf- b activity and use thereof
EP2089389A2 (en) 2006-11-01 2009-08-19 Bristol-Myers Squibb Company Heterocyclic compounds as modulators of glucocorticoid receptor, ap-1, and/or nf-kappa-b activity
WO2008057862A2 (en) 2006-11-01 2008-05-15 Bristol-Myers Squibb Company MODULATORS OF GLUCOCORTICOID RECEPTOR, AP-1, AND/OR NF-ϰB ACTIVITY AND USE THEREOF
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
CN102149710A (zh) 2008-06-24 2011-08-10 百时美施贵宝公司 糖皮质激素受体、AP-1和/或NF-κB 活性的环戊噻吩调节剂及其用途
WO2010009319A2 (en) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US8927549B2 (en) 2008-11-21 2015-01-06 High Point Pharmaceuticals, Llc Adamantyl benzamide derivatives
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
JP6606491B2 (ja) 2013-06-05 2019-11-13 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼｃの超高純度アゴニスト、その作成および使用方法
WO2015027021A1 (en) 2013-08-22 2015-02-26 Bristol-Myers Squibb Company Imide and acylurea derivatives as modulators of the glucocorticoid receptor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4584294A (en) * 1984-11-07 1986-04-22 Merck & Co., Inc. Fused tricyclic lactams as angiotensin converting enzyme inhibitors and as antihypertensive agents
ZA874106B (en) * 1986-06-13 1987-12-08 Merrell Dow Pharmaceuticals Inc. Novel antihypertensive agent
CA1337654C (en) * 1986-06-13 1995-11-28 Gary A. Flynn Fused tricyclic lactams as antihypertensive agents
US4824832A (en) * 1987-12-30 1989-04-25 Merrell Dow Pharmaceuticals Inc. Sulfhydryl containing tricyclic lactams and their pharmacological methods of use

Also Published As

Publication number Publication date
CN1058013C (zh) 2000-11-01
KR920008040A (ko) 1992-05-27
PT99267A (pt) 1992-08-31
FI914905A (fi) 1992-04-19
HU210008B (en) 1995-01-30
FI943363A0 (fi) 1994-07-14
DK0481522T3 (da) 1998-03-09
CN1061971A (zh) 1992-06-17
CN1036590C (zh) 1997-12-03
NO180718B (no) 1997-02-24
NO914092D0 (no) 1991-10-17
FI95255C (fi) 1996-01-10
CA2053340C (en) 2002-04-02
FI96691C (fi) 1996-08-12
AU642535B2 (en) 1993-10-21
DE69128516T2 (de) 1998-07-23
NZ240230A (en) 1993-01-27
GR3026222T3 (en) 1998-05-29
HU913282D0 (en) 1992-01-28
EP0481522B1 (en) 1997-12-29
JP3181335B2 (ja) 2001-07-03
PT99267B (pt) 1999-04-30
NO180718C (no) 1997-06-04
KR100372491B1 (ko) 2003-05-27
ES2114870T3 (es) 1998-06-16
IL99769A0 (en) 1992-08-18
FI914905A0 (fi) 1991-10-17
CN1166490A (zh) 1997-12-03
DE69128516D1 (de) 1998-02-05
FI95255B (fi) 1995-09-29
CA2053340A1 (en) 1992-04-19
HUT63419A (en) 1993-08-30
FI96691B (fi) 1996-04-30
EP0481522A1 (en) 1992-04-22
IL99769A (en) 1998-12-27
JPH04282382A (ja) 1992-10-07
IE913648A1 (en) 1992-04-22
FI943363A (fi) 1994-07-14
ATE161536T1 (de) 1998-01-15
AU8581991A (en) 1992-04-30

Similar Documents

Publication Publication Date Title
NO914092L (no) Nye mercaptoacetylamid-derivater som er anvendbare som inhibitorer for enkefalinase og ace
NO923744L (no) Nye 2-substituerte indan-2-mercaptoacetylamidderivater anvendbare som inhibitorer av enkefalinase og ace
NO923745L (no) Nye 2-substituerte indan-2-carboxyalkylderivater anvendbare som inhibitorer av enkefalinase og ace
NO942994L (no) Aminoacetylmercaptoacetylamidderivater som er anvendbare som inhibitorer av enkefalinase og ACE
NO944430L (no) 4-mercaptoacetylamino-[2Åbenzazepinon(3)-derivater, og anvendelse som enkefalinaseinhibitorer
NO950683L (no) Nye 2-substituterte indan-2-merkaptoacetylamidtrisykliske derivater som er anvendbare som inhibitorer av enkefalinase
NO921706D0 (no) Nye 2-merkaptomethylen-tetrahydronafthalen- og indan-2-carboxamidderivater som enkefalinaseinhibitorer

Legal Events

Date Code Title Description
MK1K Patent expired